Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640340 · ClinicalTrials.gov registry record · NA
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT01640340 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT01640340, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these combinations are commonly used, they have never been compared to each other. The purpose of this study is to record the amount of nausea and vomiting, and the amount of "rescue" medication that is used with these two different anti-emetic regimens
Interventions
- DRUG dexamethasone
- DRUG ondansetron
- DRUG aprepitant
- DRUG palonosetron hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640340
The ClinicalTrials.gov registry entry for NCT01640340 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT01640340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01640340 about?
NCT01640340 is a clinical study titled "Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)". Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused b...
What is the current status of trial NCT01640340?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2011-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01640340?
The interventions under investigation include: dexamethasone (DRUG), ondansetron (DRUG), aprepitant (DRUG), palonosetron hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01640340?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.